Hematology & Oncology Headlines
Radiation Prior to CAR-T Therapy for Multiple Myeloma Does Not Increase Toxicity
Treatment with radiation prior to chimeric antigen receptor (CAR) T-cell therapy was found to be safe and did not increase toxicity for patients with multiple myeloma (MM), according to new findings presented at the...
Cancer Specific Headlines: powered by MashupMD
Journal Reading List
Today's Top 5
5. Impact of Hematologic Malignancy and Cancer Therapy on COVID-19 Severity
#OncoAlert “Impact of hematologic malignancy and type of #cancer therapy on #COVID19 severity and mortality: lessons from a large population-based registry study” #hematology Kudos to @jgarciasu59 & @hematologiamadr https://t.co/MzfVNHm899
— Raul Cordoba, MD, PhD (@DrRaulCordoba) October 21, 2020
4. FoundationOne CDx Approved for Larotrectinib in NTRK+ Tumors
FDA approved NGS-based FoundationOne CDx to identify fusions in neurotrophic receptor tyrosine kinase genes NTRK1, NTRK2, and NTRK3, in DNA from tumor tissue from patients with solid tumors eligible for treatment with larotrectinib. https://t.co/opVoUe05jp
— FDA Oncology (@FDAOncology) October 26, 2020
3. Closing the Global Cancer Divide #ASTRO20
Very inspiring story and very important topic in Global Oncology #ASTRO20 !! Closing the Global Cancer Divide: A Health & An Equity Imperative...we need to do better #radonc!!! pic.twitter.com/8BC84y3XDM
— Therese Y. Andraos (@therese_andraos) October 26, 2020
2. The Genomic Landscape of Neuroendocrine Cervical Carcinoma
Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment Paradigms—high grade is not like small cell at molecular level: Eskander JCO P.O. https://t.co/ONMIYAW0M6
— Razelle Kurzrock, MD (@Dr_R_Kurzrock) October 27, 2020
1. Integrating Rehabilitation into Cancer Care
Improving the integration of rehabilitation into cancer care: A review of #oncology guidelines and their recommendations for #rehabilitation and #exercise https://t.co/QRerXhhGON #cancerehab #exerciseoncology @NicoleStoutPT @JulieSilverMD @KarenPhysio @DR_SantaMina @WVUCancer pic.twitter.com/kObsSMRN9A
— CA: A Cancer Journal for Clinicians (@CAonline) October 27, 2020
Cancer Nursing Today
- EWSR1 Overexpression is a Pro-oncogenic Event in Multiple Myeloma
- Single-agent Belantamab Mafodotin for Relapsed/refractory Multiple Myeloma: Analysis of the Lyophilized Presentation Cohort from the Pivotal DREAMM-2 Study
- Cancer Patients Near End of Life Still Suffer Significant Symptom Burden
- New BRAF Inhibitor Cancer Drug Shows Efficacy
- Radiation Prior to CAR-T Therapy for Multiple Myeloma Does Not Increase Toxicity